The design, synthesis and anticancer activity of new nitrogen mustard derivatives of natural indole phytoalexin 1-methoxyspirobrassinol

Neoplasma

Volumn 56, Issue 4, 2009, Pages 321-330

  Mezencev, R ^a   Kutschy, P ^b   Salayova, A ^b   Updegrove, T ^a   Mcdonald, J F ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

DNA damaging compounds; Drug resistance; Indole phytoalexin; Methoxyspirobrassinol; Nitrogen mustard

Indexed keywords

1 METHOXY 2 DEOXY 2 [N,N BIS (2' CHLOROETHYL)AMINO]SPIROBRASSINOL; ALKYLATING AGENT; CHLORMETHINE DERIVATIVE; GLUTATHIONE; MELPHALAN; PHYTOALEXIN; UNCLASSIFIED DRUG; 1 METHOXY 2 DEOXY 2 (N,N BIS(2' CHLOROETHYL)AMINO)SPIROBRASSINOL; 1-METHOXY-2-DEOXY-2-(N,N-BIS(2'-CHLOROETHYL)AMINO)SPIROBRASSINOL; ANTINEOPLASTIC AGENT; CASPASE; INDOLE DERIVATIVE; PHYTOALEXINS; TERPENE; THIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DNA DAMAGE; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; RADISH; SENSITIZATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; IC 50; METABOLISM; PATHOLOGY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA DAMAGE; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GLUTATHIONE; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; MELPHALAN; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; TERPENES; THIAZOLES; TUMOR CELLS, CULTURED;

EID: 68149089818     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_04_321     Document Type: Article

References (31)

1. Gilman A. The initial clinical trial of nitrogen mustard. Am J Surg 1963; 105: 574-578. doi:10.1016/0002-9610(63)90232-0
2. BERTINO JR. History of chemotherapy of lymphomas and description of early trials (Chapter 2). In: Mauch PM, Armitage JO, Harris NL, Dalla-Favera R, Coiffier B, editors. Lippincott Williams & Wilkins, 2003: 21-29.
3. BURCHENAL JH, MYERS WPL, CRAVER LF, et al. The nitrogen mustards in the treatment of leukemia. Cancer 1949; 2: 1-17. doi:10.1002/1097-0142(194901)2: 1<1::AID- -CNCR2820020102>3.0.CO;2-J
4. KARNOFSKY DA, ABWELMANN WH, CRAVER LF et al. The use of nitrogen mustards in the palliative treatment of carcinoma with particular reference to bronchogenic carcinoma. Cancer 1948; 1, 634-656. doi:10.1002/1097- 0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L
5. GOLDENBERG GJ, MOORE MJ. Nitrogen mustards (Chapter 1). In: Teicher BA, editor. Cancer Therapeutics. Experimental and Clinical Agents. Totowa NJ: New Humana Press, 1997: 3-23.
6. EVERETT JL, ROBERTS JJ, ROSS WCJ. Aryl-2-halogenoalkylamines. XII. Some carboxylic derivatives of NN-di-2-chloroethylaniline. J. Chem. Soc. 1953; 3: 2386-2392.
7. LUCK JM. Action of p-dichloroethyl amino-L-phenylalanine on Harding-Passey mouse melanoma. Science (Washington DC) 1956; 123: 984-985. doi:10.1126/science.123.3205.984
8. WRIGHT JE. Phosphoramide and oxazaphosphorine mustards. In: Teicher BA, editor. Cancer Therapeutics: Experimental and Clinical Agents. Totowa NJ: Humana Press Inc., 1997: 23-79.
9. KENNEDY BJ, TORKELSON JL, TORLAKOVIC. Uracil mustard revisited. Cancer 1999; 85: 2265-2272.
10. PENG GW, MARQUEZ VE, DRISCOLL JS. Potential central nervous system antitumor agents. Hydantoin derivatives. J. Med. Chem. 1975; 18: 846-849. doi:10.1021/jm00242a019
11. WEISS GR, POGGESI I, ROCHETTI M et al. A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer Clin Cancer Res 1998; 4: 53-59.
12. McClean S, Costelloe C, Denny W et al. Sequence selectivity, cross-linking efficiency and cytotoxicity of DNA-targeted 4-anilinoquinoline aniline mustards. Anticancer Drug Des 1999; 14:187-204.
13. Monde K, Takasugi M, Shirata A. Three sulphur-containing stress metabolites from Japanese radish. Phytochemistry 1995; 39: 581-586. doi:10.1016/0031-9422(95)00011-U
14. Mezencev R., Kutschy P, SALAYOVA A et al. Anticancer Properties of 2-Piperidyl Analogues of the Natural Indole Phytoalexin 1-Methoxyspirobrassinol. Chemotherapy 2008; 54: 372-378. doi:10.1159/000152027
15. Caffrey PB, Zhang Y, Frenkel GD Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in vivo. Anticancer Res 1998; 18(4C): 3021-3025.
16. Pedras MSC, Zaharia I, Sinalbins A and B, phytoalexins from Sinapis alba: elicitation, isolation, and synthesis. Phytochemistr y 2000; 55:213-216 doi:10.1016/S0031-9422(00)00277-6
17. Kutschy P, Suchy M, MONDE et al. Spirocyclization strategy toward indole phytoalexins. The first synthesis of (±)-1-methoxyspirobrassinin (±)-1-methoxyspirobrassinol, and (±)-1-methoxyspirobrassinol methyl ether. Tetrahedron Lett. 2002; 43: 9489-9492. doi:10.1016/S0040-4039(02) 02452-8
18. O'Brien J, Wilson I, Orton T et al. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 2000; 267: 5421-5426. doi:10.1046/j.1432-1327.2000.01606.x
19. AUBRY JP, BLAECKE A, LECONAET-HENCHOZS et al. Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. Cytometry. 1999; 37 :197-204. doi:10.1002/(SICI)1097-0320(19991101)37:3<197::AID- -CYTO6>3.0.CO;2-L
20. MUNSHI CB, GRAEFF R, LEE HC. Evidence for a Causal Role of CD38 Expression in Granulocytic Differentiation of Human HL-60 Cells. J Biol Chem 2002; 277: 49453-49458. doi:10.1074/jbc.M209313200
21. Žaludova R, Žakovska A, Kasparkova J, et al. DNA interactions of bifunctional dinuclear platinum(II) antitumor agents. Eur J Biochem 1997; 246: 508-517. doi:10.1111/j.1432- 1033.1997.00508x
22. de Jong S, ZIJLSTRA JG, TIMMEER-BOSSCHA H et al. Detection of DNA cross-links in tumor cells with the ethidium bromide fluorescence assay. Int J Cancer 1986; 37: 557-561. doi:10.1002/ijc.2910370414
23. GREEN JA, VISTICA DT, YOUNG RC et al. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res 1984; 44: 5427-5431.
24. HAMILTON TC, YOUNG RC, McKOY WM et al. Characterization of human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 1983; 43: 5379-5389.
25. Omoto E, Deguchi S, Takaba S et al. Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. Leukemia 1996; 10: 609-614.
26. Hartley-Asp B, GUNNARSON PO, LILJEKVIST J. Cytotoxicity and metabolism of prednimustine, chlorambucil and prednisolone in a Chinese hamster cell line. Cancer Chemother Pharmacol 1986; 16: 85-90. doi:10.1007/BF00256154
27. Panda D, MILLER HP, ISLAM K et al. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: A possible mechanistic basis for its antitumor action. Proc Natl Acad Sci USA 1997; 94: 10560-10564. doi:10.1073/ pnas.94.20.10560
28. LEONI LM, BAILEY B, REIFERT J et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008; 14: 309-317. doi:10.1158/1078- 0432. CCR-07-1061
29. Balcarova Z, Kasparkova J, Zakovska A et al. DNA interactions of a novel platinum drug, cis-[PtCl(NH3)2(N7-acyclovir)]+. Mol Pharmacol 1998; 53: 846-855
30. Garcia St, McQuillan A, Panasci L. Correlation between the cytotoxicity of melphalan and DNA crosslinks as detected by the ethidium bromide fluorescence assay in the F1 variant of B16 melanoma cells. Biochem Pharmacol. 1988; 37: 3189-3192. doi:10.1016/0006-2952(88)90319-X
31. GODWIN AK, MEISTER A, O'DWYER PJ et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992; 89: 3070-3074. doi:10.1073/pnas.89.7.3070